Get started
Work

MO01.33 CRESTONE – Clinical Study of REsponse to Seribantumab in Tumors with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210)

Year: 2021
Type: conference-abstract
DOI: 10.1016/j.jtho.2020.10.138
Authors: D. Spigel, S.N. Waqar, M.E. Burkard, J.J. Lin, Y.K. Chae, M.A. Socinski, S. Gadgeel, K.L. Reckamp, S.M. Leland, D. Plessinger, L. Kunkel, J.R. Bauman, G. Otterson, B. Halmos, S.-H. Ignatius Ou, T. Patil, Y.Y. Elamin, E.S. Kim
Institutions: Sarah Cannon, Washington University in St. Louis, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Massachusetts General Hospital, Northwestern University, AdventHealth Orlando, AdventHealth, Henry Ford Health, Cedars-Sinai Medical Center, Fox Chase Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Montefiore Medical Center, University of California, Irvine, University of Colorado Cancer Center, The University of Texas MD Anderson Cancer Center, Levine Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W3118567182
Cites:
Cited by: 4
Related to: 10